App-Quantinova.ai

Targeting PARP inhibitor resistance with Polθ inhibitors

Diana Zatreanu - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Tolinapant (ASTX660 enhances the anti-leukemic activity of Venetoclax and Dexamethasone in T cell acute lymphoblastic leukemia (T-ALL

Priyanka Sharma - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Dexamethasone

PIK3CA and PTEN mutations as drivers of osimertinib resistance in patients with NSCLC

Ursula Grazini - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

Tagrisso

V-delta-1 T cells are resident in the human lung and associate with survival in patients with non-small cell lung cancer in the TRACERx Study

Yin Wu - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Interferon Gamma

Demonstrating restoration of T cell function in exhausted T cells with IKZF3 small molecule inhibitor, Lenalidomide

Joanne Hay - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Lenalidomide

A streamlined workflow for preclinical assessment of monoclonal antibody therapies: A case study

David Cobeta Lopez - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Erbitux

In vitro responses of peripheral blood mononuclear cells in severe asthma patient treated with Mepolizumab

Fahad Alhadian - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Dexamethasone

Late Breaking Abstract - Efficacy of CSJ117 on allergen-induced asthmatic responses in mild atopic asthma patients

Gail Gauvreau - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Nitric oxide

Life Cycle Assessment (LCA and Cradle-to-Grave (CTG Carbon Footprint of a Multidose Reservoir Dry Powder Inhaler

Kristian Borenius - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Asthma

salmeterol + fluticasone

Late Breaking Abstract - Efficacy of oral prednisolone in patients with stable severe eosinophilic asthma (SEA treated with Mepolizumab

Jieqiong Yang - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Prednisolone

Relationship between baseline fraction of exhaled nitric oxide (FeNO and response to anti-IL-5/5R therapies in severe eosinophilic asthma (SEA

Joanne Kavanagh - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Benralizumab

ß2-adrenoceptor (ß2-AR dysfunction in airway smooth muscle in severe asthma: possible role of inflammatory cytokines

Jameel Hakeem - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Carbocysteine

Development and characterisation of a multi-species COPD biofilm

Bryn Short - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Erythromycin

Serum G-CSF is a non-invasive biomarker classifying bacterial/neutrophilic COPD exacerbations

Arindam Chakrabarti - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Filgrastim

Mechanisms of FeNO Non-Suppression in Severe Asthma: Analysis of Sputum Type 2 Cytokines and Chemokines

Simon Couillard - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Fluticasone propionate

Immunohistochemical evidence of increased neutrophil swarms in Cystic Fibrosis lung removed at transplantation

Kasim Jiwa - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Cystic Fibrosis

Elaszym

Respiratory outcomes pre and post nusinersen in children with spinal muscular atrophy (SMA in a tertiary UK paediatric respiratory and neurology centre

Mihaela Diaconu - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Spinal muscular atrophy

Nusinersen

Late Breaking Abstract - Anaplastic Lymphoma Kinase inhibition as an effective treatment strategy against the enhanced lung carcinogenesis and cancer angiogenesis related to decreased PTPRZ1 expression

Despoina Ntenekou - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

Crizotinib

Relative performance of nebulizers used in acute care wards

Adam Metcalf - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Salbutamol

Effect of I:E ratio on the respirable delivered dose from nebulizers

Adam Metcalf - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Salbutamol

Filters

45280 Abstracts